APX 005M

Drug Profile

APX 005M

Alternative Names: APX 005; APX 005M; EPI-0050

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Epitomics
  • Developer Apexigen; University of Texas M. D. Anderson Cancer Center
  • Class Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD40 antigen stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Solid tumours

Most Recent Events

  • 21 Mar 2017 Phase-I/II clinical trials in Malignant melanoma (Metastatic disease, Late-stage disease, Combination therapy) in USA (Intratumoural)
  • 14 Apr 2016 Pharmacodynamics data from preclinical studies in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) (3182701; 3183805)
  • 15 Mar 2016 M.D. Anderson Cancer Center and Apexigen plan a phase I/II trial in Malignant melanoma (Late-stage disease, Metastatic disease, Combination therapy) in USA (NCT02706353)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top